ACR 2026 data show 56.7% of patients with PsA met GLP-1 RA eligibility criteria, but only 15.7% were prescribed treatment.
News|Articles|July 8, 2026
First Half 2026 Rheumatology Recap
Author(s)RheumatologyLive Editorial Staff
Fact checked by: Victoria Johnson
We reviewed new psoriatic arthritis approvals as well as data readouts from head-to-head trials and milestone data in IgG4-related disease.
Advertisement
Advertisement
The first half of 2026 was among the most consequential half-years in rheumatology in recent memory, defined by a first-in-class oral approval, landmark head-to-head data, a major EULAR readout season, 2 significant guideline updates, and a string of regulatory filings that set up an eventful second half. The most significant regulatory story of the half was the March approval of deucravacitinib for psoriatic arthritis (PsA) — the first TYK2 inhibitor indicated for PsA, expanding a class already established in plaque psoriasis.
Related to this article
Two ACR 2026 abstracts report rising cardiovascular deaths in Sjögren syndrome and superior ESSDAI response with baricitinib vs hydroxychloroquine.
The FDA approved tildrakizumab for adults with active psoriatic arthritis based on two phase 3 trials showing improved ACR20 response at week 24 vs placebo.
On World Arthritis Day, TOGETHER-PsA data and 3 rheumatology/derm experts frame GLP-1 agonists as a promising — but not yet proven — adjunct therapy.
At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
Advertisement
Advertisement